{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"trastuzumab deruxtecan"},{"type":"CodeName","name":"DS-8201"},{"type":"USBrandName","name":"Enhertu"},{"type":"CodeName","name":"DS-8201a"},{"type":"CodeName","name":"WHO 10516"},{"type":"CASRegistryName","name":"1826843-81-5"}],"definition":{"html":"An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) conjugated to deruxtecan, a derivative of the camptothecin analog exatecan (DXd; DX-8951 derivative), a DNA topoisomerase 1 (topoisomerase I; Top1) inhibitor, with antineoplastic activity. Upon administration of fam-trastuzumab deruxtecan-nxki, trastuzumab targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, deruxtecan binds to and inhibits Top1-DNA complexes, which results in an inhibition of DNA replication, cell cycle arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. In addition, trastuzumab deruxtecan induces antibody-dependent cell-mediated cytotoxicity (ADCC) and causes a bystander killing effect.","text":"An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) conjugated to deruxtecan, a derivative of the camptothecin analog exatecan (DXd; DX-8951 derivative), a DNA topoisomerase 1 (topoisomerase I; Top1) inhibitor, with antineoplastic activity. Upon administration of fam-trastuzumab deruxtecan-nxki, trastuzumab targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, deruxtecan binds to and inhibits Top1-DNA complexes, which results in an inhibition of DNA replication, cell cycle arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. In addition, trastuzumab deruxtecan induces antibody-dependent cell-mediated cytotoxicity (ADCC) and causes a bystander killing effect."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/famtrastuzumabderuxtecan-nxki","text":"Fam-Trastuzumab Deruxtecan-nxki"},"nciConceptId":"C128799","nciConceptName":"Trastuzumab Deruxtecan","termId":783025,"name":"fam-trastuzumab deruxtecan-nxki","firstLetter":"f","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"trastuzumab-deruxtecan"}],"links":null}